



Please type a plus sign (+) inside this box → **+**


(M dified) PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1632  
+

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/001,278	
	Filing Date	November 1, 2001	
	First Named Inventor	Robert V. Farese, Jr.	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission	10	Attorney Docket Number	407T-927110US


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input checked="" type="checkbox"/> Copy of Search Report	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	PTO-1449 form and receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<b>Authorization to Charge Deposit Account</b> Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group, P.
Signature	
Date	4/9/03

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <u>April 10, 2003</u>			
Typed or printed name	Deborah Berwick		
Signature		Date	April 10, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on April 10, 2003



#10  
4/17/03  
**RECEIVED**

APR 15 2003

TECH CENTER 1600/2900

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By Deborah Berwick  
Deborah Berwick

Attorney Docket No. 407T-927110US  
Client Ref. No. 2001-10101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert V. Farese, Jr., et al.

Application No.: 10/001,278

Filed: November 1, 2001

For: ALPHA-TOCOPHEROL TRANSFER  
PROTEIN KNOCKOUT ANIMALS

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97 and  
§ 1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Enclosed is a copy of International Search Report for corresponding International Application No. PCT/US01/45249.

Also enclosed is an additional PTO-1449 form with additional references. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

04/17/2003 DJACOBS 00000001 500893 10001278

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Tom Hunter  
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

TH:db



INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Substitute for form 1449A-B/PTO		Complete if Known	
	Application Number		10/001,278	
	Filing Date		N vember 1, 2001	
	First Named Inventor		R bert V. Far s , Jr.	
	Group Art Unit		Unassigned	
	Examiner Name		Unassigned	
	Attorney Docket Number		407T-927110US	
Date Submitted		April 10, 2003		

RECEIVED

APR 15 2003

TECH CENTER 1600/2900


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	AA	CAPECCHI (1994) "Targeted Gene Replacement." <i>Scientific American</i> pp. 34-41.	
	BB	WALL (1996) "Transgenic Livestock: Progress and Prospects for the Future." <i>Theriogenology</i> 45:57-68	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Complete if Known	
	Application Number	10/001,278
	Filing Date	November 1, 2001
	First Named Inventor	Robert V. Fares, Jr.
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	407T-927110US
Date Submitted	April 10, 2003	

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	ARITA ET AL. (1995) "Human alpha-tocopherol transfer protein: cDNA cloning, expression and chromosomal localization." <i>Biochem. J.</i> 306: 437-443.	
	2	ARITA ET AL. (1997) "α-Tocopherol transfer protein stimulates the secretion of -tocopherol from a cultured liver cell line through a brefeldin A-insensitive pathway." <i>Proc. Natl. Acad. Sci., USA</i> , 94: 12437-12441.	
	3	AWAD ET AL. (1994) "Detection and Localization of Lipid Peroxidation in Selenium- and Vitamin E-Deficient Rats Using F <sub>2</sub> -Isoprostanes." <i>American Institute of Nutrition</i> 124: 810-816.	
	4	BURTON ET AL. (1998) "Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E." <i>The American Journal of Clinical Nutrition</i> 67(4): 669-684.	
	5	CATIGNANI AND BIERI (1977) "Rat Liver Alpha-Tocopherol Binding Protein." <i>Biochimica et Biophysica Acta</i> 497: 349-357.	
	6	CAVALIER ET AL. (1998) "Ataxia with Isolated Vitamin E Deficiency: Heterogeneity of Mutation and Phenotypic Variability in a Large Number of Families." <i>American Journal of Human Genetics</i> 62: 301-310.	
	7	CHAN (1998) "Vitamin E and Atherosclerosis." <i>The Journal of Nutrition</i> 128: 1593-1596.	
	8	EVANS AND BISHOP (1922) "On the Existence of a Hitherto Unrecognised Dietary Factor Essential for Reproduction," <i>Science</i> 56: 650-651.	
	9	FOLLIS (1958) pp 159-170 in <i>Deficiency Disease: Functional and Structural Changes in Mammalia Which Result from Exogenous or Endogenous Lack of One or More Essential Nutrients</i> , (Charles C. Thomas, Springfield, IL).	
	10	HANKS ET AL. (1995) "Rescue of the En-1 Mutant Phenotype by Replacement of En-1 with En-2." <i>Science</i> 269: 679-682.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Substitute for form 1449A-B/PTO		Complete if Known	
	Application Number	10/001,278		
	Filing Date	November 1, 2001		
	First Named Inventor	Robert V. Far se, Jr.		
	Group Art Unit	Unassign d		
	Examiner Name	Unassign d		
	Attorney Docket Number	407T-927110US		
Date Submitted	April 10, 2003			

RECEIVED


APR 15 2003

TECH CENTER 1600/2900

11	HENTATI ET AL. (1996) "Human Alpha-Tocopherol Transfer Protein: Gene Structure and Mutations in Familial Vitamin E Deficiency." <i>American Neurological Association</i> 39: 295-300.
12	KEANEY ET AL. (1999) "Vitamin E and vascular homeostasis: implications for atherosclerosis." <i>FASEB Journal</i> 13: 965-976.
13	KUTNINK ET AL. (1987) "An Internal Standard Method for the Unattended High-Performance Liquid Chromatographic Analysis of Ascorbic Acid in Blood Components." <i>Analytical BioChemistry</i> 166: 424-430.
14	LANG ET AL. (1986) "Simultaneous Determination of Tocopherols, Ubiquinols, and Ubiquinones in Blood, Plasma, Tissue Homogenates, and Subcellular Fractions." <i>Analytical Biochemistry</i> 157: 106-116.
15	MEINER ET AL. (1996) "Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: Evidence suggesting multiple cholesterol esterification enzymes in mammals." <i>Proc. Natl. Acad. Sci., USA</i> , 93: 14041-14046.
16	MORROW AND ROBERTS (1997) "The isoprostanes: unique bioactive products of lipid peroxidation." <i>Progress in Lipid Research</i> 36(1): 1-21.
17	NAKASHIMA ET AL. (1994) "ApoE-Deficient Mice Develop Lesions of All Phases of Atherosclerosis Throughout the Arterial Tree." <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 14: 133-140.
18	OUAHCHI ET AL. (1995) "Atazia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein." <i>Nature Genetics</i> 9: 141-145.
19	PALINSKI ET AL. (1995) "Increased Autoantibody Titers Against Epitopes of Oxidised LLD in LLD Receptors-Deficient Mice with Increased Atherosclerosis." <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> . 15: 1569-1576.
20	PIEDRAHITA ET AL. (1992) "Generation of Mice Carrying a Mutant Apolipoprotein E Gene Inactivated by Gene Targeting in Embryonic Stem Cells." <i>Proc. Natl. Acad. Sci., USA</i> 89:4471-4475.
21	PLUMP ET AL. (1992) "Severe Hypercholesterolemia and Atherosclerosis In Apolipoprotein E-Deficient Mice Created by Homologous Recombination In ES Cells." <i>Cell</i> 71: 343-353.
22	PODDA ET AL. (1996) "Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinols, and ubiquinones." <i>Journal of Lipid Research</i> 37: 893-901.
23	PRATICÒ ET AL. (1998) "Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice." <i>Nature Medicine</i> 4(10): 1189-1192.
24	PURCELL-HUYNH ET AL. (1995) "Transgenic Mice Expressing High Levels of Human Apolipoprotein B Develop Severe Atherosclerotic Lesions in Response to a High-Fat Diet." <i>Journal of Clinical Investigation</i> . 95: 2246-2257.
25	SASAHARA ET AL. (1994) "Inhibition of Hypercholesterolemia-induced Atherosclerosis in the Nonhuman Primate by Probucoo." <i>Journal of Clinical Investigation</i> 94: 155-164.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Complete if Known		<b>RECEIVED</b>  APR 15 2003  TECH CENTER 1600/2900
	Application Number	10/001,278	
	Filing Date	N vemb r 1, 2001	
	First Named Inventor	R bert V. Fares , Jr.	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
	Attorney Docket Number	407T-927110US	
Date Submitted	April 10, 2002		

26	SATO ET AL. (1993) "Primary structure of alpha-tocopherol transfer protein from rat liver. Homology with cellular retinaldehyde-binding protein." <i>The Journal of Biological Chemistry</i> 268: 17705-17710.
27	SHAISH ET AL. (1999) "Dietary Beta-Catotene and Alpha-Tocopherol Combination Does Not Inhibit Atherogenesis in an ApoE-Deficient Mouse Model." <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 19: 1470-1475.
28	SHIH ET AL. (2000) "Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis." <i>The Journal of Biological Chemistry</i> 275: 17527-17535.
29	SOKOL ET AL. (1988) "Isolated vitamin E deficiency in the absence of fat malabsorption - familial and sopradic cases: Characterization and investigation of causes." <i>J. Lab. Clin. Med.</i> 111: 548-559.
30	STEINBERG (1997) "Lewis A. Conner Memorial Lecture: Oxidative Modification of LDL and Atherogenesis." <i>Circulation</i> 95: 1062-1071.
31	STEINBERG ET AL. (1989) "Beyond Cholesterol: Modifications of Low-Density Lipoprotein That Increase Its Atherogenicity." <i>The New England Journal of Medicine</i> 320: 915-924.
32	SULKIN AND SULKIN (1960) "Intimal Lesions in Arteries of Vit. E Deficient Rats." <i>Proc. Soc. Exp. Biol. Med.</i> 103: 111-115.
33	TERASAWA ET AL. (1999) "Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinol, and ubiquinones." <i>Journal of Lipid Research</i> 40: 1967-1977.
34	TRABER AND ARAI (1999) "Molecular Mechanisms Of Vitamin E Transport." <i>Annu. Rev. Nutr.</i> 19: 343-355.
35	TRABER AND PACKER (1995) "Vitamin E: beyond antioxidant function." <i>The American Journal of Clinical Nutrition</i> . 62: 1501S-1509S.
36	UPSTON, ET AL. (1999) "Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement." <i>FASEB Journal</i> 13: 977-994.
37	URNER (1931) "The Intra-Uterine Changes in the Pregnant Albino Rat (MUS Norvegicus) Deprived of Vitamin E." <i>Anat. Rec.</i> 50: 175-187.
38	WALLDIUS ET AL. (1994) "The Effect of Probucol of Femoral Atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)." <i>The American Journal of Cardiology</i> 74: 875-883.
39	YUSUF ET AL. (2000) "Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators." <i>The New England Journal of Medicine</i> 342: 154-160.
40	ZHANG ET AL. (1992) "Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E." <i>Science</i> 258: 468-471.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.